Literature DB >> 19126267

Mutational, inhibitory and microcalorimetric analyses of Plasmodium falciparum TMP kinase. Implications for drug discovery.

M Kandeel1, T Ando, Y Kitamura, M Abdel-Aziz, Y Kitade.   

Abstract

Plasmodium falciparum thymidylate kinase (PfTMK) can tolerate a range of substrates, which distinguishes it from other thymidylate kinases. The enzyme not only phosphorylates TMP and dUMP but can also tolerate bulkier purines, namely, dGMP, GMP, and dIMP. In order to probe the flexibility of PfTMK in accommodating ligands of various sizes, we developed 6 mutant enzymes and subjected these to thermodynamic, inhibitory and catalytic evaluation. Kinase activity was markedly affected by introducing a larger lysine residue instead of A111. The lack of the hydroxyl group after inducing mutation of Y107F affected enzyme activity, and had a more severe impact on dGMP kinase activity. PfTMK can be inhibited by both purine and pyrimidine nucleosides, raising the possibility of developing highly selective drugs. Thermodynamic analysis revealed that enthalpic forces govern both purine and pyrimidine nucleoside monophosphate binding, and the binding affinity of both substrates was highly comparable. The heat produced due to dGMP binding is lower than that attributable to TMP. This indicates that additional interactions occur with TMP, which may be lost with larger dGMP. Targeting PfTMK not only affects thymidine nucleotide synthesis but may also affect purine nucleotides, and thus the enzyme represents an attractive antimicrobial target.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19126267     DOI: 10.1017/S0031182008005301

Source DB:  PubMed          Journal:  Parasitology        ISSN: 0031-1820            Impact factor:   3.234


  7 in total

Review 1.  Purine and pyrimidine pathways as targets in Plasmodium falciparum.

Authors:  María Belén Cassera; Yong Zhang; Keith Z Hazleton; Vern L Schramm
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

2.  Targeting the Plasmodium falciparum's Thymidylate Monophosphate Kinase for the Identification of Novel Antimalarial Natural Compounds.

Authors:  Kweku S Enninful; Samuel K Kwofie; Mark Tetteh-Tsifoanya; Amanda N L Lamptey; Georgina Djameh; Samuel Nyarko; Anita Ghansah; Michael D Wilson
Journal:  Front Cell Infect Microbiol       Date:  2022-05-25       Impact factor: 6.073

3.  Metabolic drug targets of the cytosine metabolism pathways in the dromedary camel (Camelus dromedarius) and blood parasite Trypanosoma evansi.

Authors:  Mahmoud Kandeel; Abdulla Al-Taher
Journal:  Trop Anim Health Prod       Date:  2020-09-14       Impact factor: 1.559

4.  The structural basis of unique substrate recognition by Plasmodium thymidylate kinase: Molecular dynamics simulation and inhibitory studies.

Authors:  Mahmoud Kandeel; Yukio Kitade; Abdulla Al-Taher; Mohammed Al-Nazawi
Journal:  PLoS One       Date:  2019-02-07       Impact factor: 3.240

5.  Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease.

Authors:  Mahmoud Kandeel; Mohammed Al-Nazawi
Journal:  Life Sci       Date:  2020-04-03       Impact factor: 5.037

6.  Drug repurposing for SARS-CoV-2 main protease: Molecular docking and molecular dynamics investigations.

Authors:  Samia E Omer; Tawasol M Ibrahim; Omer A Krar; Amna M Ali; Alaa A Makki; Walaa Ibraheem; Abdulrahim A Alzain
Journal:  Biochem Biophys Rep       Date:  2022-01-31

7.  Synthesis and evaluation of α-thymidine analogues as novel antimalarials.

Authors:  Huaqing Cui; Juana Carrero-Lérida; Ana P G Silva; Jean L Whittingham; James A Brannigan; Luis M Ruiz-Pérez; Kevin D Read; Keith S Wilson; Dolores González-Pacanowska; Ian H Gilbert
Journal:  J Med Chem       Date:  2012-12-14       Impact factor: 7.446

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.